Source: Annual Congress 2002 - COPD - Drug therapy 1
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Eliraz, T. Bengtsson, M. Bogdan, G. Johansson, D. Osmanilev, S. Soliman, G. Tornling, (Rehovot, Israel; Lund, Uppsala, Sweden; Bukharest, Romania; Sofia, Bulgaria). Formoterol turbuhaler is effective and safe as maintenance or maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 2002; 20: Suppl. 38, 1580

Member's Comments

No comment yet.

Related content which might interest you: Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003 Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 1075 Year: 2004 The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001 What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002 Triple therapy with Fluticasone furoate/Umeclidinium/Vilanterol compared with dual bronchodilation or triple therapy with inhaled corticosteroids/dual bronchodilation in patients with chronic obstructive pulmonary disease Source: Virtual Congress 2020 – Investigations of COPD Year: 2020 Salmeterol, added to usual therapy, is an effective bronchodilator over 12 months of treatment in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002 Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002 The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007 Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001 In chronic obstructive pulmonary disease, a combination of ipratropium and long-acting beta2-agonists is more effective than either agent alone Source: Eur Respir J 2001; 18: Suppl. 33, 211s Year: 2001 How frequent is bronchodilator reversibility in patients with stable asthma bronchiale and chronic obstructive lung disease (COPD) receiving maintenance therapy? Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012 Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004 The role of bronchodilator treatment in the prevention of exacerbations of COPD Source: Eur Respir J 2012; 40: 1545-1554 Year: 2012 Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 177s Year: 2001 Once-daily QVA149 has a good safety profile in patients with COPD Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Source: Eur Respir J 2003; 21: 912 Year: 2003 Tiotropium as essential maintenance therapy in COPD Source: Eur Respir Rev 2006; 15: 51-57 Year: 2006 Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 52s Year: 2002 Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD) Source: Eur Respir J 2004; 24: Suppl. 48, 252s Year: 2004